Miravant's (MRVT) Confirmatory Phase III Clinical Trial Of PHOTREX(TM) In Patients With Age-Related Macular Degeneration Is Underway
10/19/2005 5:13:19 PM
SANTA BARBARA, Calif.--(BUSINESS WIRE)--Oct. 10, 2005--Miravant Medical Technologies (OTCBB:MRVT), a pharmaceutical development company specializing in PhotoPoint(R) photodynamic therapy (PDT), today confirmed that patient enrollment is underway in its Phase III clinical trial of PHOTREX(TM) (SnET2) for wet age-related macular degeneration (AMD). This multi-center, placebo controlled study is a confirmatory trial designed to fulfill the requirements for additional clinical data as outlined in an "approvable" letter received from the FDA following its review of the company's NDA submission.
comments powered by